Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Early study checks how food affects new drug AZD5004

NCT ID NCT07455825

First seen Mar 10, 2026 · Last updated Jun 22, 2026 · Updated 14 times

Summary

This early-stage study tested different oral versions of the drug AZD5004 in 65 healthy adults. The goal was to see how the body absorbs and processes each version, and whether taking it with food changes those effects. The study is complete, but results are not yet available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site

    Glendale, California, 91206, United States

  • Research Site

    Baltimore, Maryland, 21225, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AZD5004

What this could lead to

If successful, this study could help determine the best way to take AZD5004 in future trials, possibly leading to a new treatment option.

What could go wrong

This is an early Phase 1 study in healthy people, not patients. It only looks at how the drug moves through the body, not whether it works for any disease. Results may not apply to patients.

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.